Skip to content
Screener

GoodRx Holdings, Inc. GDRX Prescription transactions revenue — Sales and marketing

Similar metrics at other companies

NerdWallet, Inc. logo
NRDSOther marketing — Sales and marketing
$29.3M-23.9%
NerdWallet, Inc. logo
NRDSPerformance marketing — Sales and marketing
$116.1M+29.7%
Thryv Holdings, Inc. logo
THRYMarketing Services — Sales and marketing
$11.36M-35.0%
Idexx Laboratories logo
IDXXCAG segment revenue — Sales and marketing
$175.25M+12.2%
Idexx Laboratories logo
IDXXLPD segment revenue — Sales and marketing
$175.25M+12.2%
Arlo Technologies logo
ARLOShipping and Handling — Sales and marketing
$800K-13.5%

Other financials

Income statement

See full
Revenue$200.4M-1.3%
Gross profit$179.4M-5.4%
Operating income$23.6M-11.9%
Net income$8.5M-33.5%
EPS (diluted)$0.02-50.0%

Balance sheet

See full
Cash & equivalents$296.1M+5.3%
Total debt$539.0M-1.6%
Total equity$647.6M+0.7%
Total assets$2.3B+77.7%

Cash flow

See full
Operating cash flow$80.8M+63.0%
CapEx$362.0K-7.2%
Free cash flow$80.5M+63.6%

Valuation

See full
Market cap$1.26B+3.8%
Enterprise value$1.5B+1.6%
P/E77.3×+42.3×
P/S1.6×+0.1×

Profitability

See full
Gross margin90.8%-2.8pp
Operating margin9.5%-1.6pp
Net margin2.1%-2.3pp
FCF margin25.1%+1.4pp

Returns & leverage

See full
Return on equity2.5%-2.8pp
Debt / equity0.8×0.0×
Current ratio1.4×-2.8×

Where this comes from

Reported directly by GoodRx Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:SellingAndMarketingExpense.

The source filing: GoodRx Holdings, Inc.’s 10-K, filed February 26, 2026.

Filed
Feb 25, 2026, 7:00 PM EST
Fiscal year
FY2025
Accession
0001809519-26-000031
(in thousands, except per share amounts)Year Ended December 31, 2025Year Ended December 31, 2024Year Ended December 31, 2023
Costs and operating expenses:
Cost of revenue, exclusive of depreciation and amortization presented separately below57,59748,21566,925
Product development and technology121,026123,749135,836
Sales and marketing331,560367,114341,328
General and administrative113,960117,862125,515
Depreciation and amortization85,21869,538107,668
Total costs and operating expenses709,361726,478777,272
Operating income (loss)87,49265,846(27,007)

Item 16. Form 10-K Summary.

FAQ

What is GoodRx Holdings, Inc.'s prescription transactions revenue — sales and marketing?
GoodRx Holdings, Inc. (GDRX) reported prescription transactions revenue — sales and marketing of $0 in Q4 2025.
What is the long-term trend for GoodRx Holdings, Inc.'s prescription transactions revenue — sales and marketing?
Over 3 years (2022 to 2025), GoodRx Holdings, Inc.'s prescription transactions revenue — sales and marketing has grown at a -100.0% compound annual growth rate (CAGR), from $24.7M to $0.
What does prescription transactions revenue — sales and marketing mean?
This metric represents the expenditures dedicated to advertising, brand promotion, and customer acquisition efforts specifically aimed at driving volume for the prescription transactions segment. It reflects the company's investment strategy to grow its user base and increase transaction frequency within the digital healthcare platform. Analyzing this spend relative to revenue growth helps evaluate the return on investment for marketing initiatives and the sustainability of customer acquisition costs.

Ask your AI about GoodRx Holdings, Inc.'s prescription transactions revenue — sales and marketing.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude